Skip to content
HowShorted

CytomX Therapeutics, Inc. short interest in 2018

In 2018, CytomX Therapeutics, Inc.'s disclosed short interest ran from 3.02% of shares outstanding on 12 Jan 2018 to 5.30% on 31 Dec 2018, a change of +2.28 percentage points. The year's high was 7.29% on 29 Jun 2018 and its low 2.42% on 31 Jan 2018, averaging 4.59% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 9.96 days on 31 Aug 2018. Full history: CytomX Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for CytomX Therapeutics, Inc. in 2018

2018 in figures

Start of year
3.02% (12 Jan 2018)
End of year
5.30% (31 Dec 2018)
Change
+2.28 pp
High
7.29% (29 Jun 2018)
Low
2.42% (31 Jan 2018)
Average
4.59%
Highest days to cover
9.96 (31 Aug 2018)
SEC filings marked
9

Every report in 2018

CytomX Therapeutics, Inc. short interest in 2018
SettlementShort interestDays to coverFilings since previous
12 Jan 20183.02%2.91
31 Jan 20182.42%3.18
15 Feb 20182.61%3.35
28 Feb 20182.87%3.96
15 Mar 20183.09%2.0510-K filed, results (8-K)
29 Mar 20182.66%2.41
13 Apr 20182.70%3.45
30 Apr 20182.68%3.54
15 May 20183.57%3.8210-Q filed, results (8-K)
31 May 20184.53%5.42
15 Jun 20185.32%3.13
29 Jun 20187.29%5.73
13 Jul 20187.00%5.03results (8-K)
31 Jul 20185.59%3.96
15 Aug 20185.35%7.3210-Q filed, results (8-K)
31 Aug 20185.38%9.96
14 Sep 20185.03%4.77
28 Sep 20186.20%7.25
15 Oct 20186.00%7.51
31 Oct 20185.84%7.38
15 Nov 20185.55%4.7410-Q filed, results (8-K)
30 Nov 20184.92%7.10
14 Dec 20185.18%4.67
31 Dec 20185.30%4.46

See also: CytomX Therapeutics, Inc.'s full history · most shorted US stocks of 2018 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.